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Summary
BACKGROUND: Lung transplantation (LTx) provides a vi-
able option for the survival of end-stage lung diseases.
Besides survival as a clinical outcome measure, health-
related quality of life (HRQoL) and psychological distress
have become important outcomes in studies investigating
the effectiveness of LTx in the short- and long-term.
OBJECTIVE: To assess and compare HRQoL trajectories
of patients after LTx prior to and over a follow-up period of
three years post-transplant, and to identify differences re-
garding distress, HRQoL and patient-related outcomes.
METHODS: In this longitudinal study, 27 lung transplant
recipients were prospectively examined for psychological
distress (Symptom Checklist short version-9; SCL-K-9),
health-related quality of life (EuroQOL five dimensions
questionnaire; EQ-5D), depression (HADS-Depression
scale), and socio-demographic and medical outcomes at
two weeks, three months, six months and three years fol-
lowing LTx. Additionally, potential outcome-related predic-
tors for LTx-outcomes at three years post-transplant were
assessed. Data were collected in accordance with guide-
lines set by the STROBE (strengthening the reporting of
observational studies in epidemiology) statement.
RESULTS: Lung transplant recipients showed the most
pronounced improvements in HRQoL and reduction in
psychological distress between two weeks and three
months post-transplant, with relative stable HRQoL and
distress trajectories thereafter. The most important predic-
tors of poor somatic health trajectories over time were the
pre-transplant disease severity score and the pre-trans-
plant HADS-Depression score. In addition, idiopathic pul-
monary fibrosis (IPF) and pre-transplant extracorporeal
membrane oxygenation (ECMO)-use predicted poorer
survival, while cystic fibrosis was associated with better
survival three years post-transplant.
COMCLUSION: Lung transplantation yields significant
survival and HRQoL benefits, with its peak improvement at
three months post-transplant. The majority of patients can
preserve these health changes in the long-term. Patients
with a worse HRQoL and higher psychological distress
at six months post-transplant tended to have a poorer
survival post-transplant. Other risk factors for poorer sur-
vival included IPF, pre-transplant ECMO-use, pre-trans-
plant symptoms of depression, high pre-transplant dis-
ease severity and worse somatic disease severity
trajectories. The majority of LTx-recipients were unable to
work due to illness-related reasons.
Keywords: lung transplantation, psychological distress,
health-related quality of life, longitudinal study
Introduction
Lung transplantation is an established therapeutic option
for various forms of end-stage lung disease when alterna-
tive treatment options are no longer effective. Lung trans-
plantation leads to successful outcomes in carefully select-
ed patients, characterised by reduced disability, extended
survival and improved health-related quality of life
(HRQoL) [1, 2]. More than 50,000 lung transplantations
have been performed worldwide, with increasing survival
rates over time [3]. Over the past two decades, there has
been a remarkable improvement in the short- and long-
term survival rates of lung transplant (LTx) patients. In
Switzerland, one-, three- and five-year survival rates of
87%, 75% and 69% have been achieved, which are compa-
rable to the results of international programs [4, 5].
Besides survival, HRQoL and psychological distress have
become important clinical outcome measures in studies in-
vestigating the effectiveness of lung transplantation in the
short- and long-term [6]. Furthermore, psychological fac-
tors such as psychological distress, depression and poor
quality of life have emerged as independent risk factors for
post-transplant survival [7, 8]. Numerous studies have con-
clusively demonstrated a clear improvement in HRQoL af-
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ter lung transplantation [2, 6, 9–13]. Specifically, results
from longitudinal studies reported a significant improve-
ment in the HRQoL in LTx-recipients, especially within
the first six months post-transplant, with a relatively stable
HRQoL thereafter [14, 15]. Nonetheless, the individual
trajectories of HRQoL over time are less clear in LTx-re-
cipients, as their health is often hampered by numerous
post-operative complications and the side effects of im-
munosuppressive therapy [16, 17]. Indeed, few studies
have examined distinct HRQoL trajectories within the
same patients over time. In a study of our own, we found
distinctive post-operative psychological distress and
HRQoL trajectories. More precisely, almost a quarter of
the investigated LTx-recipients suffered from elevated dis-
tress and substantially impaired HRQoL, with no improve-
ment over the first six months post-transplant. Strong pre-
dictors for poor post-transplant outcomes were underlying
diagnosis, older age, disease severity and length of hospital
stay [18].
The purposes of this study were to assess and compare the
development of HRQoL trajectories in patients after lung
transplantation over a follow-up period of three years, and
to identify differences regarding distress and HRQoL, as
well as the socio-demographic and medical characteristics,
between living and deceased LTx-recipients.
Methods
Study population
Between January 2012 and April 2014, 72 lung transplants
were performed at the Transplant Centre of the University
Hospital of Zurich, Switzerland. Forty-three of these lung
transplant recipients met the following inclusion criteria:
(1) older than 18 years of age, (2) able and/or willing to
provide informed consent, and (3) able and/or willing to
complete questionnaires in German. Out of these 43 pa-
tients, three withdrew from participation for medical or
personal reasons during the first six months after transplan-
tation (n = 40). Within the three-year post-transplant peri-
od, 10 of the 40 participants died. In addition, during data
collection for T4, three patients withdrew from participa-
tion for medical or personal reasons. The final study sam-
ple included 27 lung transplant recipients who survived
the three-year follow-up period and 10 LTx-recipients who
died before the last assessment time-point. The response
rate was 90% (40/43 LTx-patients).
Design and procedures
In this prospective, longitudinal follow-up study, 27 lung
transplant recipients were assessed at five different mea-
surement time-points (T0: pre-transplant; T1: two weeks;
T2: three months; T3: six months; and T4: three years after
transplantation). Following approval from the Ethics Com-
mittee of the Canton Zurich, Switzerland, all patients pro-
vided written informed consent prior to their participation.
Eligible patients were asked to fill in a set of question-
naires. The first two assessments, at T0 and T1, were con-
ducted at bedside during hospitalisation. The follow-up as-
sessments at T2 and T3 were performed during regular
transplant clinic outpatient visits at the University Hospi-
tal Zurich, and T4 was collected via questionnaires sent by
mail. Data was collected in accordance with guidelines set
by the STROBE (strengthening the reporting of observa-
tional studies in epidemiology) statement [19].
Measures
EuroQuol (EQ-5D)
The EQ-5D, a self-administered psychometric instrument,
was used to assess health-related quality of life. The ques-
tionnaire evaluates five dimensions of health: mobility,
self-care, usual activities, pain/discomfort and anxiety/de-
pression. Each dimension could be rated on a three-point
Likert scale of no problems, some problems or severe
problems. A single global score (range 0–100) was gener-
ated using the sum model as described by Hinz et al. [20].
In the current study, the EQ-5D showed good internal con-
sistency over the four measurement time points, ranging
between 0.64 and 0.77 (Cronbach’s alpha).
The Symptom Checklist (SCL-K-9)
The German version of the Symptom Checklist short ver-
sion-9 (SCL-K-9 [21]) form was used to assess overall
psychological distress. The SCL-K-9 is comprised of nine
items, rated on a 5-point Likert scale (0 = not at all to
4 = very strong). The SCL-K-9 is highly correlated with
the original SCL-90-R [22], and presents similarly good
psychometric properties and sensitivity to change, with a
Cronbach’s alpha of 0.87. In this study, internal consisten-
cy over the three measurement time points was good, with
a Cronbach’s alpha ranging from 0.75 to 0.84.
The patients’ medical records were used to retrieve all the
socio-demographic and medical information. In order to
generate a pre-transplant baseline score for quality of life,
the pre-transplant EQ-5D of the Swiss Transplant Cohort
study (STCS) was used. More details on the design of the
STCS can be found elsewhere [23, 24].
Somatic Disease Severity Score (SDSS)
In addition, a somatic disease severity score (SDSS) was
calculated by the treating transplant pulmonologist (MMS)
to assess the individual disease trajectories over time, in-
cluding the pre-transplant health status, the health status at
six months, and at three years post-transplant. The scores
reached from 1 = favourable, 2 = regular to 3 = poor.
The eight-item SDSS for the somatic evolution of LTx-re-
cipients over time was calculated based on the transplant
pulmonologist’s assessment of the number of complica-
tions in the assessment period compared to a predefined
expected evolution. The assessment parameters included
the evolution of (1) lung function, (2) renal function
(eGFR), (3) weight and (4) C-reactive protein (CRP). The
number of infectious complications requiring (5) addition-
al antibiotic treatment (oral or intravenous) and (6) other
additional anti-infectious treatments, i.e. antifungal or an-
tiviral treatments, as well as (7) steroid augmentation (oral
or intravenous), were also evaluated, as was hospitalisation
(8) for any complication, including infections, allograft
dysfunction or gastrointestinal problems.
All parameters were categorised as “better than expected”
(cat. 1), “expected” (cat. 2) and “worse than expected”
(cat. 3). For the overall somatic assessment, the most fre-
quent category of the eight parameter evaluations (mode)
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was taken as the final result of the somatic evolution in the
time frame studied.
The expected evolution was an increase in or stability of
lung function (for all patients) and an increase in or sta-
bility of weight for cachectic (BMI <18.5 kg/m2) and nor-
mal weight patients prior to transplant, or a decrease in
or stability of weight for pre-transplant overweight (BMI
>25 kg/m2) patients. Weight changes of 5% were consid-
ered relevant. Stability of renal function was expected. One
oral or one intravenous antibiotic treatment episode was
expected for each six-month period. One additional an-
ti-infectious therapy episode with antiviral or antifungal
medication was expected for every six-month follow-up
period, despite use of regular antiviral and antifungal pro-
phylaxis for all patients. Either one modification of im-
munosuppression medication (switch of drug or steroid
augmentation) or one hospitalisation was expected per six-
month follow-up period.
The whole six-month period prior to the assessment time
point was considered, but to get an idea of the long-term
evolution at three years, the whole one-year period prior to
the assessment time point was briefly assessed (focusing
on CRP and pulmonary function) to put the last six months
into the context of that year.
Changes in parameters of 10% or more were considered
relevant unless specified otherwise. For CRP, values <5
(considered the normal reference in our setting) were con-
sidered low. CRP values of 5-19 were considered moderate
(intermittent elevation to this level may be expected), and
values of 20 or higher were relevant elevations in these
highly immunosuppressed patients taking multiple med-
ications.
Additionally, the pre-transplant co-morbidity index devel-
oped by Barrios et al. [25], which includes ten extra-pul-
monary comorbidities that may negatively impact short-
and long-term post-operative trajectories, was used. This
comorbidity index comprises the following factors: (1)
body mass index >30 kg/m2, (2) osteoporosis, (3) insulin-
dependent diabetes, (4) arterial hypertension, (5) cardiac
disease, (6) chronic liver disease, (7) diverticulosis, (8)
gastroesophageal reflux, (9) history of malignancy, and
(10) psychiatric disorders. The comorbidity index was
computed by summing up the number of comorbidities for
each patient. Values between 0 and 10 were possible.
Statistical analysis
For the sociodemographic and medical data at T1 we used
Excel and reported in either counts and percentages or
means and ranges. We compared the results between the
living patients (n = 27) and the patients (n = 10) who
died after measurement time point T3. For the remaining
statistical analyses, the Statistical Package for the Social
Sciences (IBM SPSS, version 25) was used. Descriptive
statistics are shown as means and standard deviations. A
multivariate test, a general linear model with repeated mea-
sures and repeated contrasts, was conducted for the depen-
dent variables SCL-K-9 and EQ-5D, with time as the with-
in-subject factor. Assumptions for all analyses with this
model were checked in terms of Mauchly’s test of spheric-
ity. Assumptions were met, with the exception of a signif-
icant Mauchly’s test for the global severity index (GSI) of
the SCL-K-9, which was considered with a Greenhouse-
Geisser correction. A p-value smaller than 0.05 was con-
sidered statistically significant.
Due to the small sample size, we did not carry out analysis
of the statistical significance between the two groups (liv-
ing and deceased lung transplant recipients) regarding
HRQoL and psychological distress over the three-year fol-
low-up period.
Results
Out of the initial sample of 40 LTx-recipients for the six-
month follow-up study, 27 (68%) could be included in the
three-year follow-up. Ten (25%) patients died within the
three-year follow-up period, and three patients (8%) with-
drew from the study due to personal and medical reasons.
Detailed socio-demographics and clinical characteristics of
the LTx-recipients are summarised in table 1. Comparison
of the living and deceased LTx-recipients at T4 revealed
some differences. In particular, patients who suffered from
idiopathic pulmonary fibrosis were more likely to die. In
contrast, patients with cystic fibrosis had a better survival
rate after lung transplantation relative to patients with other
lung diseases. In addition, the LTx-recipients who died
over the three-year follow-up period more frequently had a
poor pre-transplant disease severity score (20% vs. 11%),
more frequently suffered from bronchiolitis obliterans syn-
drome (BOS) (70% vs. 17%), and had more frequently
used extracorporeal membrane oxygenation (ECMO) di-
rectly prior to transplantation (60% vs. 22%).
Comparing the pre-transplant HRQoL data provided by the
STCS with the post-transplant HRQoL data of this study
(table 2) revealed a moderate impairment of HRQoL be-
fore transplantation (M = 70.43; SD = 17.70). In contrast,
long-term analysis of our data showed a significant im-
provement in both, HRQoL (p < 0.001) and psychologi-
cal stress (p = 0.003) between T1 and T2, specifically be-
tween two weeks and three months post-transplant (table
2). Furthermore, after an initial reduction in psychological
distress between two weeks and three months, the SCL-
K-9 outcomes for the remaining measurement points were
stable, reaching a value of 0.43 at T4, almost a community-
based standard value (fig. 1). Similarly, after an initial
improvement in HRQoL between two weeks and three
months post-transplant, HRQoL remained stable during
the three-year follow-up period (fig. 2).
Interestingly, patients who died within the three-year fol-
low-up period reported better quality of life and less psy-
chological distress immediately after transplantation, but
had impaired HRQoL and increased stress levels six
months post-transplant relative to the LTx-recipients who
were still alive at the three-year follow-up (figs 1 and 2).
Correlation analyses (table 3) revealed statistically signif-
icant positive correlations between the T0 pre-transplant
disease severity score and both the somatic disease severity
score for poor somatic health trajectories (r = 0.432; p <
0.01) and the psychological distress at T3 (r = 0.391; p
< 0.05). There were statistically significant positive cor-
relations between the pre-transplant depression score and
the T0 pre-transplant disease severity score (r = 0.403; p
< 0.01), the psychological distress at T3 (r = 0.668; p <
0.001) and at T4 (r = 0.501; p < 0.01), as well as an inverse
correlation for quality of life at T3 (r = 0.425 p < 0.01).
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There were also statistically significant inverse correla-
tions between the T0 pre-transplant disease severity score
and quality of life at T0 (r = -0.376; p <0.05) and at T3 (r
= -0.424; p <0.01). The relationship described above was
less clear at T4. Furthermore, the somatic disease severity
score for poor somatic health trajectories at T3 was signifi-
cantly positively correlated with the somatic disease sever-
ity score for poor somatic health trajectories at T4 (r =
0.566; p <0.01).
Discussion
This longitudinal three-year follow-up study assessed and
compared the development of the HRQoL and distress tra-
jectories of 27 LTx-recipients. Our results indicate a clear
benefit from lung transplantation, with its peak improve-
ment occurring three months post-transplant. In line with
previous studies [6, 26–28], the majority of patients in
this cohort reported a deterioration in HRQoL prior to
lung transplantation, followed by a major impairment in
HRQoL and increase in psychological distress two weeks
after transplantation. Three months post-transplant, most
of the LTx-recipients had experienced a dramatic improve-
ment in HRQoL and a significant reduction of psycholog-
ical distress. The post-transplant improvement in HRQoL
Table 1: Socio-demographic and medical characteristics.
Alive Dead
n = 27 (73%) n = 10 (27%)
Sex (n, %)
‒ Male 15 56% 6 60%
‒ Female 11 41% 4 40%
Age (years; mean, range) 48.63 19‒66 46.40 19‒66
Married (n, %) 13 48% 4 40%
Education level (n, %)
‒ Elementary 6 22% 1 10%
‒ Secondary 13 48% 6 60%
‒ Tertiary 8 30% 3 30%
Underlying diagnosis (n, %)
‒ CF 11 41% 2 20%
‒ COPD 11 41% 4 40%
‒ IPF 4 15% 3 30%
‒ Other 4 15% 1 10%
SDSS T4 (n, %)
‒ Favourable 10 37% 0 0%
‒ Regular 13 48% 0 0%
‒ Poor 4 15% 0 0%
T0 HADS-D (mean, range) 4.7 1‒12 5.8 1‒11
Comorbidities (mean, range) 1.44 0‒4 2.60 1‒4
Nr. of days on waiting list (mean, range) 289.81 10‒992 171.00 16‒439
ECMO use (n, %) 6 22% 6 60%
Nr. of days in ICU pLTx (mean, range) 6.59 2‒29 8.30 2‒24
Length of stay (weeks; mean, range) 5.52 3‒14 6.30 3‒12
Nr. of hospitalizations pLTx (mean, range) 0.59 0‒2 1.30 0‒4
Nr. of infections pLTx (mean, range) 0.44 0‒2 1.10 0‒3
Nr. of rejections pLTX (mean, range) 0.04 0‒1 0.30 0‒2
Use of antidepressants pLTx (n, %) 6 22% 4 40%
Working ability pLTx (n, %) 6 22% 0 0
Abbreviations. CF = cystic fibrosis; COPD = chronic obstructive pulmonary disease; IPF = idiopathic pulmonary fibrosis; BOS = bronchiolitis obliterans syndrome; SDSS = somatic
disease severity score; T0 HADS-D = Hospital Anxiety and Depression Scale - Depression; ECMO = extracorporeal membrane oxygenation; ICU = intensive care unit; pLTx =
post lung transplantation. ‒ Note. Somatic disease severity refers to the post-transplant health status at T4 and was assessed by the treating transplant pneumonologist (MMS)
by use of a somatic disease severity score resulting in one of three categories (1 = favourable; 2 = regular; 3 = poor).
Table 2: Pre- and post-transplant quality of life and psychological distress in lung transplant recipients.
T0 T1 T2 T3 T4 Contrasts
M (SD) M (SD) M (SD) M (SD) M (SD) Wilks' Lambda p-values p-values
T0 vs. T1 0.06
EQ-5D 70.43 (17.70) 62.17 (25.75) 85.22 (15.04) 87.39 (13.22) 89.57 (12.24) 0.29 <0.001 T1 vs. T2 <0.001
n = 23 T2 vs. T3 0.26
T3 vs. T4 0.37
T1 vs. T2 <0.001
SCL-K-9 - 1.05 (0.73) 0.53 (0.38) 0.45 (0.38) 0.43 (0.34) 0.57 0.003 T2 vs. T3 0.17
n = 27 T3 vs. T4 0.78
M = mean; SD = standard deviation; EQ-5D = EuroQOL five dimensions questionnaire; SCL-K-9 = Symptom Checklist short version-9. T0 = pre-transplant; T1 = two weeks
post-transplant; T2 = three months post-transplant; T3 = six months post-transplant; T4 = three years post-transplant.
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and reduction of psychological distress remained relatively
stable over the three-year follow-up period. The stability
of the improvement in HRQoL and the reduction of psy-
chological distress over the entire three-year follow-up pe-
riod may be attributed to advances in surgical techniques,
improved post-transplant management concepts and long-
term patient follow-up by the transplant pulmonologists
[4].
In a second analytic step, we analysed predictors of poor
transplant outcomes.
Figure 1: Health-related quality of life over time (T0 – T4). T0 =
pre-transplant; T1 = two weeks post-transplant; T2 = three months
post-transplant, T3 = six months post-transplant; T4 = three years
post-transplant
Figure 2: Psychological distress over time (T1 – T4). T0 = pre-
transplant; T1 = two weeks post-transplant; T2 = three months
post-transplant, T3 = six months post-transplant; T4 = three years
post-transplant
Patients with idiopathic pulmonary fibrosis (IPF) and pa-
tients who required the use of ECMO pre-transplant were
clearly more likely to die, whereas patients with cystic fi-
brosis (CF) showed a better survival rate during the three-
year follow-up period. Furthermore, pre-transplant depres-
sion was associated with poorer HRQoL and higher levels
of psychological distress post-transplant, demonstrating
that patients with pre-transplant depression represent a risk
population for post-transplant complications. These results
are consistent with previous results in the lung transplant
literature [18, 29–31].
The most important predictor of poor post-transplant tra-
jectories was the pre-transplant disease severity score,
highlighting the importance of integrating this evaluation
tool into clinical practice. Due to the shortage of donor or-
gans, it is critical that the patients selected are those who
are most likely to benefit from lung transplantation. As-
sessing a disease severity score prior to lung transplanta-
tion could present a promising tool to improve the alloca-
tion of donor lungs and the survival of patients undergoing
lung transplantation. However, the disease severity score
used in this study has not yet been validated or standard-
ised, and therefore the predictive value of this tool remains
uncertain. Despite this limitation, the pre-transplant sever-
ity score appeared to correlate with the outcomes of our
studied cohort. Larger long-term studies are needed to de-
termine whether a disease severity score can improve the
overall allocation and survival of eligible LTx-patients.
Interestingly, the periodical collection of a somatic disease
severity score seems to be a stable predictor of somatic
health trajectories over the post-transplant time. These
study results require confirmation in a larger clinical sam-
ple.
Professional reintegration was found to be an important
predictor of HRQoL following transplantation [32], al-
though few studies have examined employment following
lung transplantation. Similar to other studies focusing on
work ability after lung transplantation [32, 33], the per-
centage of LTx-recipients in our study returning to work
was relatively low, at 22% within the time frame studied.
All of them were patients who survived the three-year fol-
low-up period. Unfortunately, the number of LTx-recip-
ients remaining in an employed position decreased over
time due to illness-related reasons, and early retirement or
disability compensation was the consequence.
While most other studies described a sample of living pa-
tients, we used the information about deaths occurring in
the six months post-transplant to identify differences re-
Table 3: Bivariate correlations between pre-transplant disease severity score, somatic disease severity score and mental health outcomes.
Pre-Tx DSS T3 SDSS T4 SDSS HADS-D T0 T0 EQ-5D T3 EQ-5D T4 EQ-5D T3 SCL-K-9 T4 SCL-K-9
Pre-Tx DSS 1 0.450** 0.214 0.403* ‒0.376* ‒0.424** 0.228 0.391* 0.312
T3 SDSS 0.450** 1 0.445* 0.333 ‒0.433* ‒0.218 ‒0.137 0.417* 0.157
T4 SDSS 0.214 0.445** 1 0.119 ‒0.074 ‒0.189 ‒0.363 0.093 0.416*
T0 HADS-D 0.403 0.333 0.119 1 ‒0.535** ‒0.425* ‒0.106 0.668* 0.501*
T0 EQ5D ‒0.376* ‒0.433* ‒0.074 ‒0.535** 1 0.520** 0.378 ‒0.386* ‒0.094
T3 EQ5D ‒0.424** ‒0.218 ‒0.189 ‒0.425* 0.520** 1 0.684** ‒0.571** ‒0.219
T4 EQ5D ‒0.228 ‒0.137 ‒0.363 ‒0.106 0.378 0.684** 1 ‒0.188 ‒0.424*
T3 SCL-K 0.391* 0.417* 0.093 0.668* ‒0.386* ‒0.571** ‒0.188 1 0.502**
T4 SCL-K 0.312 0.157 0.416* 0.501* ‒0.094 ‒0.219 ‒0.424* 0.502** 1
Pre-Tx DSS = pre-transplant disease severity score; HADS-D = Hospital Anxiety Depression Score-Depression; SDSS = somatic disease severity score, EQ-5D = EuroQOL five
dimensions questionnaire; SCL-K-9 = Symptom Checklist short version-9. * p < 0.05, ** p < 0.01
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garding HRQoL and psychological distress, as well as so-
ciodemographic and medical information, between living
and deceased LTx-recipients. Interestingly, we found that
patients who died during the three-year follow-up period
reported better HRQoL and less psychological distress at
T1 relative to LTx-recipients who were alive at T4, but did
not experience an improvement in HRQoL and a reduc-
tion of psychological distress between T2 and T3. Thus,
patients with poorer HRQoL and higher psychological dis-
tress at six months post-transplant tended to have a poorer
survival post-transplant.
The long-term care of LTx-recipients is focused on the pre-
vention and management of complications, optimisation
of immunosuppression, treatment of medical comorbidi-
ties, and returning to independent daily living [34]. Due
to the inter-individual variability of post-operative HRQoL
trajectories over time, interventional strategies, including
psychiatric and psychosocial counselling, should be of-
fered pre-, peri- and post-operatively throughout the pa-
tient’s post-transplant recovery and adjustment.
Strengths and limitations
The present study has some limitations. Firstly, our data
were based on a small sample size from a single centre
study. Thus, the generalisability of the results may be lim-
ited, and they may not be applicable to all transplant pro-
grams or allocation systems. Furthermore, the present find-
ings need to be replicated by larger cohorts. Secondly,
our non-somatic data were based solely on patients’ self-
reporting, representing the subjective perspective of the
study participants at certain time points. Another weakness
is that the EQ-5D is a generic, preference-based measure.
A disease-specific measure could be more sensitive to
health changes than a generic one [2]. The EQ-5D was
chosen as the outcome measure due to its being easy to
complete and its previous use in lung transplant recipients
[1].
Counterbalancing these limitations are the notable
strengths of our approach. By quantifying HRQoL prior to
transplantation as well as repeatedly following transplanta-
tion patients for up to three years, we explicitly attempted
to account for selection and survivorship bias, which is an
important limitation in the existing literature [2].
Conclusion
Lung transplantation results in significant HRQoL and sur-
vival benefits in the majority of LTx-recipients in the short-
as well as in the long-term. Overall, HRQoL increased
and psychological distress decreased significantly between
two weeks and three months post-transplant, and remained
relatively stable for up to three years post-transplant. We
found that poorer HRQoL and higher psychological dis-
tress at six months post-transplant were associated with
subsequent mortality. Other risk factors for poorer survival
included IPF, pre-transplant ECMO-use, higher disease
severity and BOS. The majority of LTx-recipients were un-
able to work because of illness-related reasons. The inte-
gration of a pre-transplant disease severity index in clini-
cal practice may present a promising tool to estimate the
overall success of lung transplantation and to improve the
allocation of donor lungs and the survival of patients un-
dergoing lung transplantation. Future research on LTx-re-
lated outcome predictors is necessary for the development
of tailored psychosocial interventions.
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